-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1044 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1044 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1044 in Duchenne Muscular Dystrophy Drug Details: AOC-1044 is under...
-
Product Insights
Myotonic Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Myotonic Dystrophy - Drugs In Development, 2023’, provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Muscle Atrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Atrophy - Drugs In Development, 2023’, provides an overview of the Muscle Atrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Facioscapulohumeral Muscular Dystrophy (FSHD) - Drugs In Development, 2023’, provides an overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewNet Present Value Model: Ultragenyx Pharmaceutical Inc’s Setrusumab
Empower your strategies with our Net Present Value Model: Ultragenyx Pharmaceutical Inc's Setrusumab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.